Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02360202
Other study ID # 2014/110/HP
Secondary ID 2014-002804-26
Status Recruiting
Phase Phase 4
First received January 7, 2015
Last updated August 29, 2017
Start date April 2015
Est. completion date December 2017

Study information

Verified date August 2017
Source University Hospital, Rouen
Contact Sophie Duvert Lehembre, Doctor
Phone 2 32 88 68 41
Email sophie.duvert-lehembre@chu-rouen.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical observation frequently shows a paradoxical effect of topical corticosteroids in charge of a sudden melting of edema in the first days of treatment, which could be due to mobilization of extracellular. No study has shown the value of this measure in patients treated with topical steroids. This uncertainty, coupled with the observation of the paradoxical effects of topical steroids on edema are some patients that despite the systemic absorption of clobetasol propionate, a salt-free diet is not currently recommended practice.


Description:

The main objective of the study is to evaluate whether there is fluid retention after introduction of clobetasol propionate treatment from 10 g/day dosage to 40 g / day in patients with bullous pemphigoid. Bio-impedance is a noninvasive device for measuring with an electric current of low intensity the different volumes of the human body. A preliminary experiment of impedance measurements in some patients with bullous pemphigoid (examination requested as part of a nutritional assessment) showed that these patients had mostly a total water loss without dehydration, corresponding to a significant undernutrition during 1 month of treatment, possibly related to muscle wasting and protein loss by skin erosions without obvious argument for fluid retention, justifying reproduce these measures on a larger number of patients and the other to accurately assess the evolution of nutritional parameters during the first month of treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date December 2017
Est. primary completion date November 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient with age higher than 18

- Patient with bullous pemphigoid,

- Patient treated by local corticosteroid therapy (clobetasol propionate cream) but not yet processed or for less than 48 hours,

- Signed informed consent.

- Patient affiliated to Social Security Regimen

- Effective contraception in women of childbearing age (for postmenopausal women, confirmatory diagnosis of menopause will be collected)

Exclusion Criteria:

- Concomitant treatment with corticosteroids

- Recent introduction or recent (<6 weeks) treatment with diuretics, angiotensin-converting enzyme, receptor antagonist or anti-angiotensin renin (aliskiren)

- contraindication to the use of Clobetasol propionate (DERMOVAL and CLARELUX)

- Patient on salt diet (<or = to 5 g / d)

- Patients carry a defibrillator or a pace maker

- Amputated Patient

- Pregnant and lactating

- Patient with Urinary Incontinency

- Recent heart decompensation in the last 6 weeks

- known Nephrotic Syndrome

- known or Severe hepatic impairment

- Hypoalbuminaemia less than 20 g / l

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Impedance analysis
Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate. impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle
Drug:
Clobetasol Propionate cream treatment
clobetasol propionate treatment initiated following French recommendations

Locations

Country Name City State
France Rouen University Hospital Rouen

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Rouen Société de Dermatologie Française

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in fluid retention at day 30 Change from Baseline in extra-cellular water volume at day 30 measured by bioimpedance analysis Day 30
Secondary Change from Baseline in fluid retention at day 7 Change from Baseline in extra-cellular water volume at day 7 measured by bioimpedance analysis Day 7
Secondary Weight variation between day 1 and day 30 Day 30
Secondary Urinary Sodium level variation between day 1 and day 30 Day 30
Secondary Urinary creatinin level variation between day 1 and day 30 Day 30
Secondary Brain Natriuretic Peptide level variation between day 1 and day 30 Day 30
Secondary Change from Baseline in nutritional parameters at day 30 bioimpedance analysis, C Reactive Protein level, albumin level, daily diet diary, Buzby index Day 30
Secondary Change from Baseline in bullous pemphigoid disease severity index at day 30 BPDAI questionary assessment Day 30
Secondary Change from Baseline in bullous pemphigoid disease severity index at day 7 BPDAI questionary assessment Day 7
Secondary Change from Baseline in corticoid administration dosage at days 30 Evaluation of corticoid dosage between day 1 and day 30 Day 30
See also
  Status Clinical Trial Phase
Terminated NCT03286582 - A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid Phase 2
Completed NCT02837965 - Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
Recruiting NCT03636763 - Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
Recruiting NCT00802243 - Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Phase 2
Completed NCT05649579 - Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
Active, not recruiting NCT04206553 - A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Phase 2/Phase 3
Completed NCT00431119 - Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid Phase 2
Completed NCT04563923 - Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody Phase 2
Completed NCT03320798 - Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients N/A
Completed NCT03272958 - Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid
Completed NCT02883894 - Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid N/A
Completed NCT00809822 - Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Phase 2
Recruiting NCT05594472 - Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Phase 3
Withdrawn NCT05061771 - Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) Phase 3
Not yet recruiting NCT04128176 - Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid Phase 3
Recruiting NCT05284929 - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Terminated NCT04612790 - A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. Phase 3
Recruiting NCT05681481 - A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid Phase 3
Completed NCT00286325 - Rituximab in the Treatment of Patients With Bullous Pemphigoid Phase 1/Phase 2
Completed NCT04728854 - Telederm and Bullous Pemphigoid